118 completed, 49 terminated, 23 unknown, 16 recruiting. 133 Phase 2, 113 Phase 1, 9 Early Phase 1, 8 Phase 3, 5 Phase 4.
Follow IL-2: new trials by email Literature Review of IL-2 trials Research Report on IL-2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced Melanoma Resection of PET (high) and PET (low) Tumors, Lifileucel Manufacturing Clinical v Research, Chemotherapy Regimen - Unresectable or Metastatic Melanoma | Early Phase 1 | Not yet recruiting | Abramson Cancer Center at Penn Medicine | 10 | 2026-10-01 | 2026-07-13 |
| Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2 - Malignant Pleural Effusion, Malignant Mesothelioma | Phase 1 | Recruiting | David Bartlett, MD | 10 | 2026-06-03 | 2026-08-04 |
| Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT AdaptNK, Fludarabine, Cyclophosphamide - Relapsed Adult AML, Refractory AML | Phase 1 / Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 18 | 2026-05-08 | 2026-05-19 |
| Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2 (IL-2) - Malignant Pleural Effusion, Malignant Mesothelioma | Phase 1 | Recruiting | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | 10 | 2026-05-01 | 2026-04-07 |
| TIL Therapy in cSCC and MCC LN-145, Cyclophosphamide, Fludarabine - Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma | Phase 2 | Recruiting | Karam Khaddour, MD, MS | 14 | 2026-02-10 | 2026-02-13 |
| Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK - Cancer, Breast Cancer | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 85 | 2026-02-01 | 2026-02-18 |
| Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors GT201, IL-2, PD-1 inhibitor - Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | Grit Biotechnology | 78 | 2025-11-01 | 2026-08-19 |
| A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases CNTY-101, IL-2, Lymphodepleting Chemotherapy - Systemic Lupus Erythematosus, Lupus Nephritis | Phase 1 | Active not recruiting | Century Therapeutics, Inc. | 6 | 2025-02-06 | 2026-01-08 |
| A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors Cyclophosphamide, Fludarabine, KSQ-004EX - Select Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 141 | 2024-11-21 | 2026-10-05 |
| Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML Rabbit Anti thymocyte globulin, Busulfan, Fludarabine - AML, Childhood, Aml | Phase 1 / Phase 2 | Recruiting | Washington University School of Medicine | 68 | 2024-11-15 | 2026-08-24 |
| TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC TBio-4101, Pembrolizumab, Platinum based chemotherapy - Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 7 | 2024-03-14 | 2026-09-15 |
| A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors KSQ-001EX, Interleukin-2, Cyclophosphamide - Advanced Solid Tumor, Melanoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 15 | 2024-01-31 | 2026-08-10 |
| TIL Therapy for Patients With Advanced Solid Tumors Tumor-infiltrating lymphocytes, IL-2 - Advanced Breast Cancer, Advanced Lung Cancer | Phase 1 | Unknown | NeogenTC | 12 | 2024-01-01 | 2023-10-30 |
| Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma Biospecimen Collection, Cyclophosphamide, Echocardiography - Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma | Phase 2 | Completed | University of Kansas Medical Center | 11 | 2023-12-21 | 2026-04-30 |
| Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer Sentinel Lymph Node Biopsy (SLNB), Doxorubicin, Epirubicin - Breast Neoplasms | Phase 1 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 24 | 2023-11-01 | 2023-11-08 |
| Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer Surgery for harvesting tumor-draining lymph nodes, Cyclophosphamide, Fludarabine - Breast Neoplasms | Phase 1 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 24 | 2023-11-01 | 2023-11-08 |
| Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer Surgery for harvesting tumor-draining lymph nodes, Cyclophosphamide, Fludarabine - Breast Neoplasms | Phase 1 / Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 170 | 2023-08-01 | 2023-08-08 |
| Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer Sentinel Lymph Node Biopsy (SLNB), Doxorubicin, Epirubicin - Breast Neoplasms | Phase 1 / Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 196 | 2023-08-01 | 2023-08-08 |
| Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML Cytokine induced memory-like NK cells, Fludarabine, Ara-C - Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | Phase 2 | Withdrawn | Washington University School of Medicine | 2023-06-30 | 2023-04-04 | |
| A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer Radiotherapy, PD-1/PD-L1 inhibitor, Granulocyte-macrophage colony-stimulating factor subcutaneous injection - Advanced Solid Tumor, Refractory Tumor | Phase 2 | Unknown | Second Affiliated Hospital of Soochow University | 30 | 2023-06-16 | 2023-09-21 |
Showing 20 of 231. Sign in to see all of them.
Melanoma (57) · Leukemia, Myeloid, Acute (28) · Carcinoma, Renal Cell (22) · Neoplasm Metastasis (17) · Breast Neoplasms (14) · Leukemia (14) · Lymphoma, Non-Hodgkin (14) · Neoplasms (13) · Kidney Neoplasms (12) · Lymphoma (12) · Carcinoma, Non-Small-Cell Lung (11) · Leukemia, Lymphocytic, Chronic, B-Cell (11) · Ovarian Neoplasms (11) · Congenital Abnormalities (9) · Skin Neoplasms (9)
National Cancer Institute (NCI) (31) · Masonic Cancer Center, University of Minnesota (22) · M.D. Anderson Cancer Center (16) · Fred Hutchinson Cancer Center (11) · H. Lee Moffitt Cancer Center and Research Institute (9) · National Institute of Allergy and Infectious Diseases (NIAID) (7) · Dana-Farber Cancer Institute (5) · Fate Therapeutics (5) · Inge Marie Svane (5) · St. Jude Children's Research Hospital (5) · Second Affiliated Hospital of Soochow University (4) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (4) · Washington University School of Medicine (4) · Beijing YouAn Hospital (3) · Fujian Cancer Hospital (3)
United States (165) · China (33) · Denmark (6) · Spain (6) · United Kingdom (6) · France (5) · Italy (5) · Australia (4) · Israel (4) · Canada (3) · Germany (3) · Netherlands (3) · Sweden (3) · Argentina (2) · Austria (2)
Erwei Song, M.D., Ph.D. (4) · Steven A Rosenberg, M.D. (4) · Cassian Yee (3) · Jeffrey Miller, MD (3) · Rodabe N. Amaria, MD (3) · Steven Rosenberg, M.D. (3) · Amanda Cashen, M.D. (2) · Inge Marie Svane, Prof., MD (2) · James Yang, M.D. (2) · Jeffrey S. Miller, M.D. (2) · John Koreth, MBBS, DPhil (2) · Jun Lu, Director (2) · Leona Holmberg (2) · Melissa Geller, MD (2)
PMID 22555974, PMID 23861247, PMID 27641687, PMID 24719405, PMID 30573690, PMID 32747469, PMID 33986124, PMID 11359672, PMID 12810695, PMID 15206062, PMID 16710345, PMID 16947019, PMID 16982775, PMID 17919105, PMID 18157014, PMID 18256325, PMID 19010868, PMID 19128501, PMID 19304957, PMID 19430405, PMID 19828532, PMID 20056794, PMID 20186278, PMID 20413658, PMID 20522709, PMID 20668228, PMID 20812949, PMID 21632855, PMID 22129252, PMID 22160384, PMID 22308288, PMID 22353759, PMID 22721971, PMID 22911697, PMID 23377668, PMID 23546520, PMID 23575741, PMID 23586712, PMID 23650429, PMID 24055823, PMID 24063860, PMID 24265670, PMID 24504486, PMID 24573552, PMID 24870935, PMID 25154820, PMID 25428917, PMID 25688159, PMID 25838374, PMID 26186440
K12CA076930 (3), 2015 (2), 2019 (2), P01CA018029 (2), P30CA022453 (2), U10CA031946 (2), 2009 (1), 2023 (1), F32CA200253 (1), K08CA252642 (1), N01CM17102 (1), P01CA049639 (1), P01CA065493 (1), P01CA081403 (1), P01CA100265 (1)